Drugs approved | Weixinkang hydrochloride dopamine injection approved for market!

Recently, Inner Mongolia Baiyi Pharmaceutical, a wholly-owned subsidiary of Weixinkang, received the Drug Registration Certificate of dopamine hydrochloride injection approved and issued by the State Drug Administration (drug approval number: Sinomedical Approval number H20233811, Sinomedical approval number H20233812). At present, the company has begun to prepare for production and will provide more clinical treatment options for patients as soon as possible.

Dopamine hydrochloride injection is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin sepsis, cardiac operation, renal failure, congestive heart failure, etc. Shock can not be corrected after blood volume supplementation, especially oliguria and normal or low peripheral vascular resistance shock. Since this product can increase cardiac output, it is also used for cardiac insufficiency where digitalis and diuretics do not work. Dopamine hydrochloride injection belongs to the "National Basic Medical Insurance, Industrial injury insurance and maternity Insurance drug Catalogue (2022)" class A drugs, "National Essential Drugs Catalogue (2018 edition)" drugs. The reference preparation for this variety is INOVAN® injection, marketed by Concorde 発 Yeast キリン Co., Ltd. in 2.5ml:50mg, 5ml:100mg.

Until June 30, 2023, seven enterprises in China have passed the generic drug consistency evaluation (including the company), according to the relevant national policies and regulations, Weixinkang obtained the "Drug Registration Certificate" this time is deemed to have passed the consistency evaluation.

As a comprehensive high-tech pharmaceutical enterprise integrating drug research and development, production and sales, Weixinkang is based on the needs of patients and grasps market development opportunities. Over the years, Weixinkang has taken "caring for life, maintaining health" as its mission, adhered to pragmatic innovation, and strive to promote new products that meet clinical needs to be launched faster and more, and constantly promote the diversification of product matrix. The firm, steady and professional variety layout creates an important internal driving force for the innovation, success rate and efficiency of the R&D pipeline, and continues to promote the healthy and sustainable development of the enterprise!